PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Company ReportsAvanir Pharmaceuticals
Avanir Pharmaceuticals(AVNR)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Loading
Company Revenue
No data
Revenue by Drug
Loading
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
NuedextaDextromethorphan, Quinidine2010-10-292023-2040
Atrial fibrillation
,
Atrial flutter
,
Cardiac arrhythmias
,
Cough
,
Neurobehavioral manifestations
,
Sinusitis
,
Asthma
,
Common cold
,
Allergic rhinitis perennial
,
Urticaria
,
Vasomotor rhinitis
,
Whooping cough
,
Bronchitis
,
Pharyngitis
,
Laryngitis
,
Postoperative complications
,
Pain
,
Vomiting
,
Nausea
,
Anaphylaxis
,
Allergic conjunctivitis
,
Motion sickness
,
Tobacco use disorder
,
Attention deficit disorder with hyperactivity
,
Depressive disorder
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Dextromethorphan
healthy volunteers/patients
,
schizophrenia
,
depression
,
treatment-resistant depressive disorder
,
major depressive disorder
,
depressive disorder
,
dyskinesias
,
psychomotor agitation
,
multiple sclerosis
,
neuralgia
,
migraine disorders
,
disease progression
,
parkinson disease
,
sclerosis
,
amyotrophic lateral sclerosis
,
pain
,
diabetic neuropathies
,
motor neuron disease
,
pseudobulbar palsy
,
alzheimer disease
,
stroke
,
traumatic brain injuries
,
brain injuries
,
dementia
Quinidine gluconate
healthy volunteers/patients
,
schizophrenia
,
depression
,
treatment-resistant depressive disorder
,
major depressive disorder
,
depressive disorder
,
dyskinesias
,
psychomotor agitation
,
neuralgia
,
migraine disorders
,
disease progression
,
sclerosis
,
parkinson disease
,
multiple sclerosis
,
amyotrophic lateral sclerosis
,
pain
,
diabetic neuropathies
,
motor neuron disease
,
pseudobulbar palsy
,
alzheimer disease
,
stroke
,
traumatic brain injuries
,
brain injuries
,
dementia
Quinidine polygalacturonate
healthy volunteers/patients
,
schizophrenia
,
depression
,
treatment-resistant depressive disorder
,
major depressive disorder
,
depressive disorder
,
dyskinesias
,
psychomotor agitation
,
neuralgia
,
migraine disorders
,
disease progression
,
sclerosis
,
parkinson disease
,
multiple sclerosis
,
amyotrophic lateral sclerosis
,
pain
,
diabetic neuropathies
,
motor neuron disease
,
pseudobulbar palsy
,
alzheimer disease
,
stroke
,
traumatic brain injuries
,
brain injuries
,
dementia
Quinidine
healthy volunteers/patients
,
schizophrenia
,
depression
,
treatment-resistant depressive disorder
,
major depressive disorder
,
depressive disorder
,
dyskinesias
,
psychomotor agitation
,
neuralgia
,
migraine disorders
,
disease progression
,
sclerosis
,
parkinson disease
,
multiple sclerosis
,
amyotrophic lateral sclerosis
,
pain
,
diabetic neuropathies
,
motor neuron disease
,
pseudobulbar palsy
,
alzheimer disease
,
stroke
,
traumatic brain injuries
,
brain injuries
,
dementia
Alfacalcidol
parkinson disease
,
dyskinesias
,
migraine disorders
,
disease progression
Tiratricol
healthy volunteers/patients
,
depression
,
treatment-resistant depressive disorder
,
major depressive disorder
,
depressive disorder
,
parkinson disease
,
dyskinesias
,
psychomotor agitation
,
multiple sclerosis
,
neuralgia
,
sclerosis
,
migraine disorders
,
disease progression
,
amyotrophic lateral sclerosis
,
pseudobulbar palsy
,
alzheimer disease
,
stroke
,
traumatic brain injuries
,
brain injuries
,
dementia
Neurodex
pain
,
diabetic neuropathies
Pba
amyotrophic lateral sclerosis
,
pseudobulbar palsy
,
stroke
,
traumatic brain injuries
,
brain injuries
,
dementia
,
alzheimer disease
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use